Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

March 18, 2008 Approval Letter - Adacel

March 18, 2008

Our STN BL 125111/102

Sanofi Pasteur Limited

Attn: Gary K. Chikami, M.D.

1755 Steeles Avenue West

Toronto, Ontario M2R 3T4


Dear Dr. Chikami:

We have approved your request to supplement your biologics license application for Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (ADACEL®), to include unit dose syringes as an alternate presentation.

Under this approval, the expiration date for the unit dose syringe presentation of ADACEL® will be 30 months when stored at 2-8oC. Any requests to extend the dating period beyond 30 months will require the submission of a prior approval supplement containing supporting data to your biologics license application.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. Please provide a PDF-format electronic copy.

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

/Milan S. Blake, Ph.D./

Milan S. Blake, Ph.D.

Acting Director

Division of Bacterial, Parasitic and Allergenic Products

Office of Vaccines Research and Review

Center for Biologics Evaluation and Research

Attachment: Approved Final Draft Labeling

Resources for You

Page Last Updated: 07/17/2009
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English